CELGENE INSTITUTE FOR TRANSLATIONAL RESEARCH EUROPE (CITRE), created in 2010 (United States), from 126 sister brands and 17477 competing brands. CELGENE INSTITUTE FOR TRANSLATIONAL RESEARCH EUROPE (CITRE) is owned by Celgene, listed on the stock exchange of New York The sector of CELGENE INSTITUTE FOR TRANSLATIONAL RESEARCH EUROPE (CITRE) is Drug Manufacturers.
Buy Celgene share with
(0% commission and fractional shares)
Your capital is subject to risk. Other fees apply. For more information, visit etoro.com/trading/fees.
Other brands
Celgene
-
A
-
B
-
C
- COMPROMISO 360
- CELGENE THALIDOMIDE
- C2ARE
- CELGENE i-access
- CELGENECARE
- CANCERCAN
- cintre
- CONTINUUM
- CELG
- CHIMERIC VIGOR
- CELMOD
- CELGENE MULTIPLE MYELOMA RESOURCE CENTER
- CELGENE AVILOMICS RESEARCH
- CELGENE MATRIX
- CYTUNE
- CITRE
- CELGENE INSTITUTE FOR TRANSLATIONAL RESEARCH EUROPE
- CANCER
- CELGENE COMMITTED TO IMPROVING THE LIVES OF PATIENTS WORLDWIDE
-
D
-
E
-
F
-
G
-
H
-
I
-
K
-
L
-
M
- MULTIPLE PATHWAYS, MULTIPLE TARGETS
- MULTIPLE PATHWAYS, MULTIPLE TARGETS: DRUG DISCOVERY FOR CELGENE
- MYELOMA ALLY
- MM 013
- MAPP Multinational Assessment of Psoriasis and Psoriatic Arthritis Navigating the Course of Psoriatic Disease
- MATRIX Medical Affairs Tracking Reporting and Information Xchange
- MATRIX: MEDICAL AFFAIRS TRACKING REPORT AND INFORMATION XCHANGE
- MAINSAIL
- mpact
-
N
-
O
-
P
-
Q
-
R
-
S
-
T
-
V
